Karine has been Forepont since the launch of the company in June 2017. Prior experience includes Natixis CIB North America, Head of the Fixed Income Primary Market Origination desk – CDC Marches Paris (Caisse des Dépôts et Consignations), Fixed Income Origination, VP covering European issuers
MS in Finance (203), Université Paris Dauphine – PSL
BS in Management, Université Paris Dauphine – PSL
Philippe joined Forepont in January 2021 as the partner in charge of Business development. Prior to joining Forepont, he was the Head of Distribution at Rothschild & Co, and Head of Distribution at Oddo Asset Management.
Institut Supérieur de Gestion
AMF Certification
Bruce has been Forepont’s Chief Financial Officer since June 2017.
Before Forepont, Bruce co-founded a Commodity Trading Advisor specializing in commodities and currencies in 2002.
BS in Accounting, Brooklyn College, CUNY
CPA certificate received in 1991
A member of the AICPA and NYSSCPA
Larry has been with Forepont since June 2017 and a driving force behind all initiatives in MedTech and Neuroscience.
Previously, he was the Co-Inventor of a neural network technology at Bell Laboratories, founder of OuterCurve Technologies, and Co-Founder of a women’s healthcare venture that detects breast cancer.
Master of Science & Philosophy in Computer Science, New York University
MS in Mathematics, New York University
Dr Ismail Kola joined Forepont in April 2019 as a General Partner in charge of all scientific decisions.
He has been a driving force in biotech companies like GPN Vaccines or Mobius where his experience as one of the top international chief scientific officers has proven to be key in the early success of the companies.
Prior to Forepont, Ismail held several senior executive positions in the pharmaceutical industry. He has published 159 papers in top scientific journals which have been cited over 16,000 times and has led teams that have brought numerous major medicines to the market during his 20 year career in the pharmaceutical industry.
Ismail Kola was until 2018 the CSO of UCB, His previous positions were: Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, Schering-Plough Research Institute, and Chief Scientific Officer, Schering Plough Corporation; Senior Vice President Basic Research and Site Head, Rahway, Montreal and Madrid, Merck and Chairman of Merck’s Antibacterial and Antifungal Worldwide Business Strategy Team; and Vice President Research, and Global Head, Genomics and Biotechnology at Pharmacia Corporation .
Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease for 15 years.
He is Chairman of the Board of Directors of Athersys Inc. (ATHX, Nasdaq) and a Director of GPN vaccines (Australia).
Ph.D (Med) in Medicine, University of Cape Town, South Africa
He is a Visiting Professor of Medicine at the Nuffield School of Medicine at Oxford University and also holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, USA, and Monash University Medical School, Melbourne, Australia; a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden; and is a William Pitt Fellow at Pembroke College, Cambridge University, UK
Eric founded Forepont Capital Partners in June 2017 in New York after a 20-year career in finance. He managed a 10-billion dollar alternative investment fund with awarded performance.
He also co-founded Nexar, a global asset management company (US, UK, and Europe). Nexar was acquired in 2012 by the Swiss banking group UBP.
Since 2011, Eric helped finance breakthrough medical research at major academic hospitals, mainly in Neurology. He developed strong business and personal relationships with prominent leaders in the medical community.
Eric was able to capitalize on his unique positioning at the center of a tremendous flow of information that helps to identify and better understand healthcare’s unmet needs.
